134 related articles for article (PubMed ID: 35197754)
1. Linsitinib and aspirin as the IGF1-R antagonists, inhibit regorafenib-resistant chemotherapy in colon cancer.
Guo Y; Mehrabi Nasab E; Hassanpour F; Athari SS
Saudi J Biol Sci; 2022 Feb; 29(2):872-877. PubMed ID: 35197754
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells.
Yeo CD; Kim YA; Lee HY; Kim JW; Lee SH; Kim SJ; Kwon SS; Kim YH; Kim SC
Exp Lung Res; 2017 Feb; 43(1):29-37. PubMed ID: 28394654
[TBL] [Abstract][Full Text] [Related]
4. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
[TBL] [Abstract][Full Text] [Related]
5. Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7.
Karabicici M; Azbazdar Y; Ozhan G; Senturk S; Firtina Karagonlar Z; Erdal E
Front Cell Dev Biol; 2021; 9():639779. PubMed ID: 34458250
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Leighl NB; Rizvi NA; de Lima LG; Arpornwirat W; Rudin CM; Chiappori AA; Ahn MJ; Chow LQ; Bazhenova L; Dechaphunkul A; Sunpaweravong P; Eaton K; Chen J; Medley S; Poondru S; Singh M; Steinberg J; Juergens RA; Gadgeel SM
Clin Lung Cancer; 2017 Jan; 18(1):34-42.e2. PubMed ID: 27686971
[TBL] [Abstract][Full Text] [Related]
7. Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κB signaling in esophageal squamous cell carcinoma.
Wu J; Chen K; Zhang F; Jin J; Zhang N; Li D; Ying L; Chen W; Yu H; Mao W; Su D
Cancer Med; 2017 Jun; 6(6):1353-1361. PubMed ID: 28440057
[TBL] [Abstract][Full Text] [Related]
8. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
[TBL] [Abstract][Full Text] [Related]
9. Combination of Quercetin or/and siRNA-loaded DDAB-mPEG-PCL hybrid nanoparticles reverse resistance to Regorafenib in colon cancer cells.
Shahidi S; Rostamizadeh K; Fathi M; Nedaei K; Ramazani A
BMC Complement Med Ther; 2022 Dec; 22(1):340. PubMed ID: 36575448
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of stem cell surface markers CD133, CD24, and CD44 in colorectal cancer.
Huang JL; Oshi M; Endo I; Takabe K
Am J Cancer Res; 2021; 11(10):5141-5154. PubMed ID: 34765317
[TBL] [Abstract][Full Text] [Related]
11. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
12. [TNF-α activates Wnt signaling pathway to promote the invasion of human colon cancer stem cells].
Wei X; Li X; Kong F; Ma L; Sui Y; Chen D; Xu F
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Nov; 34(11):982-988. PubMed ID: 30591106
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Barata P; Cooney M; Tyler A; Wright J; Dreicer R; Garcia JA
Invest New Drugs; 2018 Jun; 36(3):451-457. PubMed ID: 29476383
[TBL] [Abstract][Full Text] [Related]
15. Long Non-coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling.
Wei F; Wang M; Li Z; Wang Y; Zhou Y
Front Oncol; 2020; 10():291. PubMed ID: 32195190
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
Wang YJ; Zhang YK; Zhang GN; Al Rihani SB; Wei MN; Gupta P; Zhang XY; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2017 Jun; 396():145-154. PubMed ID: 28302530
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells.
Mirone G; Perna S; Shukla A; Marfe G
J Cell Physiol; 2016 May; 231(5):1097-105. PubMed ID: 26419617
[TBL] [Abstract][Full Text] [Related]
18. Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells.
Wu S; Wang X; Chen J; Chen Y
Biochem Biophys Res Commun; 2013 May; 434(4):898-903. PubMed ID: 23624503
[TBL] [Abstract][Full Text] [Related]
19. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
20. IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines.
Refolo MG; D'Alessandro R; Lippolis C; Carella N; Cavallini A; Messa C; Carr BI
Oncotarget; 2017 Nov; 8(61):103465-103476. PubMed ID: 29262576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
